<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03466983</url>
  </required_header>
  <id_info>
    <org_study_id>P-Monofer-IBD-03</org_study_id>
    <nct_id>NCT03466983</nct_id>
  </id_info>
  <brief_title>A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease</brief_title>
  <official_title>A Randomized, Double-blinded, Comparative Trial Comparing the Incidence of Hypophosphatemia in Relation to Repeated Treatment Courses of Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacosmos A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmacosmos A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment with iron isomaltoside and ferric carboxymaltose in subjects with iron deficiency&#xD;
      anaemia due to inflammatory bowel disease and comparison of the incidence of hypophosphatemia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Existing IV iron complexes differ in relation to the compounds capability to induce&#xD;
      unintended hypophosphatemia to a degree defined as medical significant.&#xD;
&#xD;
      This trial is designed evaluate the effect of IV iron isomaltoside compared to IV ferric&#xD;
      carboxymaltose on phosphate in subjects with IDA due to inflammatory bowel disease .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 23, 2018</start_date>
  <completion_date type="Actual">May 25, 2020</completion_date>
  <primary_completion_date type="Actual">May 25, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of hypophosphatemia</measure>
    <time_frame>any time from baseline to day 35</time_frame>
    <description>s-phosphate &lt; 2 mg/dL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypophosphatemia</measure>
    <time_frame>any time from baseline to week 10</time_frame>
    <description>s-phosphate &lt; 2 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of s-phosphate &lt; 1.0 mg/dL</measure>
    <time_frame>any time from baseline to day 35</time_frame>
    <description>s-phosphate &lt; 1.0 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time with hypophosphatemia</measure>
    <time_frame>number of days any time from baseline to week 10</time_frame>
    <description>time with s-phosphate &lt; 2.0 mg/dL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>IBD</condition>
  <arm_group>
    <arm_group_label>Iron Isomaltoside</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Iron Isomaltoside (Monofer) administered IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ferric Carboxymaltose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ferric Carboxymaltose (Injectafer) administered IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron Isomaltoside</intervention_name>
    <description>administered IV</description>
    <arm_group_label>Iron Isomaltoside</arm_group_label>
    <other_name>Monofer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric Carboxymaltose</intervention_name>
    <description>administered IV</description>
    <arm_group_label>Ferric Carboxymaltose</arm_group_label>
    <other_name>Ferinject</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria include:&#xD;
&#xD;
          -  Men or women ≥ 18 years&#xD;
&#xD;
          -  Subjects diagnosed with IBD&#xD;
&#xD;
          -  Hb &lt; 13 g/dL&#xD;
&#xD;
          -  Body weight ≥ 50 kg&#xD;
&#xD;
          -  S-ferritin &lt;100 ng/mL&#xD;
&#xD;
          -  eGFR ≥ 65 mL/min/1.73 m2&#xD;
&#xD;
          -  S-phosphate &gt; 2.5 mg/dL&#xD;
&#xD;
          -  Oral iron preparations are ineffective or cannot be used or where there is a clinical&#xD;
             need to de-liver iron rapidly&#xD;
&#xD;
          -  Willingness to participate and signing the Informed Consent Form (ICF)&#xD;
&#xD;
        Exclusion Criteria include:&#xD;
&#xD;
          -  Anaemia predominantly caused by factors other than IDA according to Investigator's&#xD;
             judgment&#xD;
&#xD;
          -  Hb ≥ 10 g/dL and body weight &lt; 70 kg&#xD;
&#xD;
          -  Hemochromatosis or other iron storage disorders&#xD;
&#xD;
          -  Known hypersensitivity reaction to any component of iron isomaltoside or ferric&#xD;
             carboxymaltose&#xD;
&#xD;
          -  Previous serious hypersensitivity reactions to any IV iron compounds&#xD;
&#xD;
          -  Treatment with IV iron within the last 30 days prior to screening&#xD;
&#xD;
          -  Treatment with erythropoietin or erythropoietin-stimulation agents, red blood cell&#xD;
             transfusion, radiotherapy, and/or chemotherapy within the last 30 days prior to&#xD;
             screening&#xD;
&#xD;
          -  Received an investigational drug within the last 30 days prior to screening&#xD;
&#xD;
          -  Planned surgical procedure within the trial period&#xD;
&#xD;
          -  hepatic enzymes &gt; 3 times upper limit of normal&#xD;
&#xD;
          -  Surgery under general anaesthesia within the last 30 days prior to screening&#xD;
&#xD;
          -  Any non-viral infection within the last 30 days prior to screening&#xD;
&#xD;
          -  Alcohol or drug abuse within the past 6 months&#xD;
&#xD;
          -  Untreated hyperparathyroidism&#xD;
&#xD;
          -  Kidney transplantation&#xD;
&#xD;
          -  Conditions that interfere with the subject's ability to understand the requirements of&#xD;
             the trial and/or presumable non-compliance&#xD;
&#xD;
          -  Any other laboratory abnormality, medical condition, or psychiatric disorders which,&#xD;
             in the opinion of the Investigator, will put the subject's disease management at risk&#xD;
             or may result in the subject being unable to comply with the trial requirements&#xD;
&#xD;
          -  Pregnant or nursing women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pharmacosmos Investigational Site</name>
      <address>
        <city>Silkeborg</city>
        <zip>8600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 6, 2018</study_first_submitted>
  <study_first_submitted_qc>March 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2018</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Hypophosphatemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron isomaltoside 1000</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

